{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "INNV",
  "name": "InnovAge Holding Corp.",
  "url": "https://orbyd.app/dossiers/INNV/",
  "json_url": "https://orbyd.app/dossiers/INNV.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Post-sanctions PACE turnaround still delivering (FY2026 adj-EBITDA guide $85–90M, census ~8,050 +6.9% YoY), but the tape shifted: a $12.11 52-wk high failed back into range ($11.18 close 2026-08-07), and the 2026-07-31 S-3 registered 112,988,070 shares — ~83% of the cap table — for resale by the Apax/Welsh Carson vehicle. MATURING, with supply now papered and no print until ~2026-09-08.",
  "invalidation_trigger": "A weekly close below $10.50 forfeits the July–August consolidation shelf and ends the post-sanctions recovery leg; secondary: FY2026 adjusted EBITDA below the $85M guide floor at the ~2026-09-08 print, a marketed secondary priced under the shelf, or a new CMS enrollment freeze at any center.",
  "catalyst_date": "2026-09-08",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services",
    "consumer-discretionary-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Fiscal year ends June 30; Q4/full-year results have landed on the second Tuesday of September in each of the last two years.",
    "Controlled company: TCO Group Holdings, L.P. (Apax / Welsh, Carson) holds 112,988,070 of 135,736,393 shares outstanding as of 2026-04-30.",
    "A resale shelf registers shares; InnovAge receives no proceeds from any sale under the 2026-07-31 S-3.",
    "GAAP results run lumpy against adjusted EBITDA (Q3 FY2026: -$29.9M GAAP net income vs +$30.5M adj EBITDA). Read the reconciliation each print.",
    "CMS enrollment freezes at Colorado, California and New Mexico centers broke the equity in 2021–2022; any new sanction is a direct census hit."
  ],
  "body_markdown": "## Current Thesis\nThe post-sanctions PACE turnaround (Programs of All-Inclusive Care for the Elderly) is still working at the operating line — FY2026 adjusted-EBITDA guidance was raised to $85–90M from $70–75M, census is growing again — but two things changed after the mid-July read. Price cleared the $11.85 shelf, printed a 52-week high at $12.11 and gave it back to $11.18 by the 2026-08-07 close (-7.7% from the high, RSI(14) 51.3). the Apax Partners / Welsh, Carson vehicle — roughly 83.2% of the 135,736,393 shares outstanding as of 2026-04-30, with no proceeds to the company. The fundamental leg an investor is buying is capitation-rate leverage plus resumed enrollment; the new question is who supplies the shares if it keeps working. Narrative state: MATURING, dated by the failed 2026-07/08 breakout attempt and by the resale registration landing within a day of the stock's high-water mark ($11.60 last sale on 2026-07-30, per the prospectus).\n\n## Bull Case\n- Q3 FY2026 (reported 2026-05-05): revenue $251.9M, +15.5% YoY; adjusted EBITDA $30.5M; center-level contribution margin $61.0M.\n- FY2026 guidance raised to $950–975M revenue and $85–90M adjusted EBITDA, from $925–950M / $70–75M — roughly a 20% midpoint lift to the EBITDA frame.\n- Census ~8,050 participants across 20 centers in six states as of 2026-03-31, +6.9% YoY, against an ending-census target of 7,900–8,100. The 2026-07-31 prospectus restates the same ~8,050 / 20 centers / six states, so nothing in the filing discloses a census break through late July.\n- Q2 FY2026 (reported 2026-02-03): $11.8M net income versus a $13.5M year-ago loss on $239.7M revenue, +14.7% YoY — the profitability turn spans more than one quarter.\n- Jennifer Browne appointed President & COO in May 2026, adding operating depth to the post-sanctions bench.\n- The trend structure is intact on the 2026-08-07 basis: 3-month return +47.7%, and the 52-week high at $12.11 was set within the last three weeks, so the give-back is so far a pullback inside an uptrend.\n\n## Bear Case\n- Supply is now papered. The company receives no proceeds and the filing discloses no lock-up on the selling holder, which may sell \"some, all or none\" from time to time. Registration is not a sale, but it converts a controlled cap table into a sellable one.\n- The public float is a small remainder of 135,736,393 shares outstanding once 112,988,070 sit with one holder. Any block or marketed secondary re-prices that scarcity rather than merely absorbing flow.\n- Sell-side has not followed the price. Stockanalysis.com tracks three covering analysts, all at a $7.00 target with a Hold consensus; the last recorded target change is J.P. Morgan's raise from $5 to $7 on 2026-02-23 with a Sell rating maintained. William Blair maintained Hold on 2026-05-06 and KeyBanc maintained Hold on 2026-07-20 — neither with a published target change. The 2026-08-07 close of $11.18 sits above every tracked target.\n- Q3 FY2026 carried a $29.9M GAAP net loss against $30.5M adjusted EBITDA; GAAP EPS near -$0.22 versus +$0.078 adjusted. The below-the-line charge keeps reported results lumpy.\n- Sequential census growth was +0.5% QoQ. Enrollment is regulator- and capacity-gated, so revenue runway depends on center approvals.\n- Regulatory tail is structural: CMS enrollment freezes at Colorado, California and New Mexico centers broke the equity in 2021–2022, and the mechanism is unchanged.\n- Elevated medical-loss ratios across the managed-care complex (UNH, HUM, CNC, ELV) through 2025–2026 can compress the multiple on a small-cap capitation model independent of execution.\n\n## Setup & Price Structure\nBasis: $11.18 close on 2026-08-07; 52-week high $12.11; -7.7% from that high; RSI(14) 51.3; 3-month return +47.7%. The mid-July frame was a $11.06–$11.85 coil after a run from roughly $7.70 in late March. Price resolved that coil upward, tagged $12.11, and has since returned inside the old range — the breakout has on the current basis. Continuation would show as a daily close back above $12.11 with volume expansion; the failure case is losing the $11.06 range floor and then the $10.50 shelf on a weekly basis.\n\nPositioning and crowding observables, stated as observables:\n- ~83.2% of the cap table registered for resale on 2026-07-31, days after the stock's high-water mark ($11.60 last sale 2026-07-30 per the prospectus).\n- Every tracked analyst target ($7.00) sits below the current close; no target raise on record since 2026-02-23 despite the move.\n- RSI has reset to 51.3 from an overbought move without breaking the March-to-August trend — momentum cooled, structure held.\n- No company catalyst is on the calendar yet; the earnings scheduling release has landed in late August in each of the last two years.\n\n## Catalyst Calendar (next 30 days)\n\n- ~2026-08-25 (est.): scheduling press release naming the Q4/FY2026 date. Precedent: the FY2025 scheduling release ran 2025-08-26 for a 2025-09-09 call; the FY2024 release ran 2024-08-27 for a 2024-09-10 call.\n- ~2026-09-08 (est.): Q4 and full-year FY2026 results, the first FY2027 guide, and the year-end census number. Prior two fiscal years reported on the second Tuesday of September (2025-09-09, 2024-09-10).\n\n## Elapsed catalysts\n\n- Undated, live from 2026-07-31: any 424B7 prospectus supplement, block trade or distribution-in-kind by TCO Group Holdings under the effective resale shelf. This has no calendar date and can land on any session. *(passed 9d ago)*\n\n## What Would Change Our Mind\nThe structural break to watch is the one already in progress: the $11.85–$12.11 breakout attempt failing back into the July range is the first thing in this advance that has not worked since the late-March low. If that failure extends, a weekly close below $10.50 forfeits the July–August consolidation shelf and ends the post-sanctions recovery leg as a tradable structure.\n\nOn fundamentals, the September print is the arbiter: FY2026 adjusted EBITDA landing below the $85M low end of guidance, an FY2027 EBITDA guide that does not exceed FY2026, or ending census below the 7,900 floor of the stated 7,900–8,100 target would each contradict the operating-leverage case directly. A new CMS enrollment freeze or audit finding at any center is the 2021–2022 mechanism repeating and is not a sentiment event.\n\nOn supply, a 424B7 supplement pricing a marketed secondary at a discount to the prevailing quote would put a visible clearing price on the shelf. Conversely, the case strengthens on a daily close above $12.11 that holds, paired with a September print confirming ≥$85M FY2026 adjusted EBITDA and census above 8,100, and with the resale shelf still unused.\n\n## Correlation Notes\n- Managed-care and value-based senior care: UNH, HUM, CNC, ELV set the multiple regime for capitation models. MLR headlines in that complex move INNV without any company-specific news.\n- CMS policy flow — rate notices, audit actions, PACE program guidance — is the dominant idiosyncratic driver and has historically overwhelmed operating results at this name.\n- Sponsor-overhang cohort: small caps where a private-equity vehicle holds a supermajority trade on supply expectations once a resale shelf goes effective, which decouples them from sector beta on the days a block prints.\n- Small-cap healthcare beta (Russell 2000 healthcare) matters for the multiple, but the float here is small enough that index-driven flow is a weaker explanatory variable than single-holder activity.",
  "first_seen": "2026-07-17",
  "last_analyzed": "2026-08-09T20:05:56+00:00",
  "last_synthesized": "2026-08-09",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}